Vaccines help to strengthen the immune system and protect it from dangerous, life-threatening diseases such as hepatitis, polio, tuberculosis, and others. Vaccines help the body to fight against pathogens like viruses and bacteria. Vaccines expose the body to a very small, but safe amount of weakened or dead viruses or bacteria. If the body is exposed to the infection later in life, immune system can recognize it and attack it. This is a natural method of combating infectious diseases like polio, measles, pneumonia, and others.
The global vaccines market is estimated to be valued at US$ 38,305.2 million in 2021 and is expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).
Figure 1. Global Vaccines Market Share (%) in Terms of Value, by Route of Administration, 2021
Increasing prevalence of infectious diseases is expected to drive the market growth during the forecast period.
The increasing prevalence of various infectious diseases is expected to drive the market growth during the forecast period. For instance, according to the data provided by the World Health Organization, in October 2021, an estimated 10 million people were ill with tuberculosis (TB) worldwide, of which there were 5.6 million men, 3.3 million women and 1.1 million children in 2020. According to the same source, 86% of new TB cases occurred in the 30 high TB burden countries such as India, China, Indonesia, and others in 2020.
|Base Year:||2020||Market Size in 2021:||US$ 38,305.2 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||6.8%||2028 Value Projection:||US$ 60,673.6 Mn|
AstraZeneca, GlaxoSmithKline plc., Pfizer Inc., Abbott, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Sanofi, EMERGENT, Astellas Pharma Inc., CSL Limited, Novavax, Serum Institute of India Pvt. Ltd., Bharat Biotech., Indian Immunologicals Ltd., DAIICHI SANKYO COMPANY, LIMITED., and Merck & Co., Inc.
|Restraints & Challenges:||
Figure 2. Global Vaccines Market Share (%), by Age Group, 2021
Increasing product approvals by the regulatory bodies is expected to drive market growth during the forecast period.
The increasing vaccine approvals by the regulatory bodies is expected to drive growth of the global vaccines market over the forecast period. For instance, on January 19, 2022, Covid vaccines Covaxin and Covishield, after a year of being granted emergency use authorization, were given approval for full and regular market authorization by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO).
Global Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.
The COVID-19 pandemic hampered immunization programs in countries due to lockdowns and other measures with an aim to reduce the spread of the virus. There was a collapse in the airline industry, which impacted the shipments of vaccines significantly, thereby having a negative impact on the global vaccines market. According to an article published by UNICEF in June 2020, as a consequence of the supply disruptions, countries across East and Southern Africa (ESARO), West and Central Africa (WCARO), East Asia (EAPRO), and South Asia (ROSA) indicated vaccine stocks reaching critical levels, for measles, diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b, human papillomavirus (HPV), poliomyelitis, rotavirus, and pneumococcal conjugate vaccine (PCV). According to the same source, in early May 2020, about 99 countries reported the suspension of immunization campaigns for antigens such as measles, rubella, polio, meningococcal A, yellow fever, typhoid, cholera, and tetanus/diphtheria.
However, due to increased financial support from various government and non-government organizations, research activities for COVID-19 infection and the development of COVID-19 vaccines have significantly increased, which is expected to drive the global vaccines market growth over the forecast period.
Global Vaccines Market: Restraint
The major factor that is expected to hinder growth of the global vaccines market include high cost involved in the vaccine development process and stringent government regulations for product approval. For instance, according to an article published by HEALTH AFFAIRS, in May 2021, around US$ 19.3 billion were spent on COVID-19 vaccine development by Biomedical Research and Development Authority (BARDA), a U.S. Department of Health and Human Services office alone.
Major players operating in the global vaccines market include AstraZeneca, GlaxoSmithKline plc., Pfizer Inc., Abbott, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Sanofi, EMERGENT, Astellas Pharma Inc., CSL Limited, Novavax, Serum Institute of India Pvt. Ltd., Bharat Biotech., Indian Immunologicals Ltd., DAIICHI SANKYO COMPANY, LIMITED., and Merck & Co., Inc.
Vaccination is a way to prevent infectious diseases such as polio, measles, pneumonia, and others. Vaccines contain severely weakened forms of viruses or bacteria, dead viruses or bacteria, or purified components of viruses or bacteria. After receiving a vaccine, body's immune system can remember bacteria or viruses and can fight off infections more effectively. Vaccines protect people from life-threatening and serious diseases, such as yellow fever, tuberculosis, hepatitis B, and others. There are some people who cannot get vaccinated because they may be too young or sick. Widespread vaccination can help protect such people. When a sufficient number of individuals in a population are immune to a disease, or a large proportion of a population are vaccinated, herd immunity is achieved, that acts by breaking the transmission of infection. Vaccines are mostly administered by injection (parenteral administration), but some are given orally or even nasally (in the case of flu vaccine).
Increasing regulatory approvals for vaccines are expected to drive the market growth during the forecast period. For instance, in August 2021, the U.S. Food and Drug Administration approved the Pfizer-BioNTech COVID-19 Vaccine, the first COVID-19 vaccine. The vaccine was developed in partnership by Pfizer Inc., an U.S.-based based pharmaceutical and Biotechnology Company, and BioNTech SE, a biotechnology company. It will be marketed as Comirnaty and will be used for the prevention of COVID-19 disease for individuals with 16 years of age and older. The vaccine will also continue to be available for individuals between 12 and 15 years of age under emergency use authorization (EUA) and for the administration of a third dose to certain immunocompromised people.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.